Synonyms: cyclo[Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-D-Pro-Pro-Nle(Bu)-Glu-Thr] | POL-6014 | POL6014
Compound class:
Synthetic organic
Comment: Lonodelestat is a modified cyclic peptide (macrolide) that acts as a selective inhibitor of human neutrophil elastase (hNE). It is being developed by Santhera Pharmaceuticals, under license from its originator Polyphor. In April 2020 Santhera announced a COVID-19 collaboration, in which non-clinical research will be conducted by Cold Spring Harbor Laboratory (CSHL) to further validate hNE as a target and assess lonodelestat as a potential agent for treating COVID-19-related acute respiratory distress syndrome (ARDS).
|
|
Bioactivity Comments |
A meeting poster abstract (Lacey et al., 2016; Poster 95) stated that lonodelestat inhibited NE with a similar potency to that of the endogenous peptide alpha1-proteinase inhibitor (a.k.a. alpha‐1 antitrypsin), but did not disrupt neutrophil function. The details behind these findings have not yet been been published or peer reviewed. |